Literature DB >> 20532840

Evi-1 as a critical regulator of leukemic cells.

Susumu Goyama1, Mineo Kurokawa.   

Abstract

Ecotropic viral integration site-1 (EVI-1) has been recognized as one of the dominant oncogenes associated with murine and human myeloid leukemia. Recent clinical studies demonstrated that high EVI-1 expression was an independent negative prognostic indicator of survival in leukemia patients. In addition, gene-targeting studies in mice reveal that Evi-1 is preferentially expressed in hematopoietic stem cells (HSCs) and plays an essential role in proliferation/maintenance of HSCs. Proteins associated with EVI-1, signaling pathways regulated by EVI-1, and downstream mediators of EVI-1 transcriptional regulation have been described and characterized. In this study, we summarize current knowledge regarding biochemical properties and biological functions of EVI-1, which provides a foundation for the development of novel therapeutic strategies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20532840     DOI： 10.1007/s12185-010-0618-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  33 in total

1.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.

Authors:  Boris Calmels; Cole Ferguson; Mikko O Laukkanen; Rima Adler; Marion Faulhaber; Hyeoung-Joon Kim; Stephanie Sellers; Peiman Hematti; Manfred Schmidt; Christof von Kalle; Keiko Akagi; Robert E Donahue; Cynthia E Dunbar
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

2.  Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis.

Authors:  Guang Jin; Yukari Yamazaki; Miki Takuwa; Tomoko Takahara; Keiko Kaneko; Takeshi Kuwata; Satoshi Miyata; Takuro Nakamura
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

3.  The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase.

Authors:  U Vinatzer; J Taplick; C Seiser; C Fonatsch; R Wieser
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

Review 4.  The yin-yang of PR-domain family genes in tumorigenesis.

Authors:  G L Jiang; S Huang
Journal:  Histol Histopathol       Date:  2000-01       Impact factor: 2.303

5.  The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.

Authors:  M Kurokawa; K Mitani; T Yamagata; T Takahashi; K Izutsu; S Ogawa; T Moriguchi; E Nishida; Y Yazaki; H Hirai
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

6.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

7.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

8.  EVI1 induces myelodysplastic syndrome in mice.

Authors:  Silvia Buonamici; Donglan Li; Yiqing Chi; Rui Zhao; Xuerong Wang; Larry Brace; Hongyu Ni; Yogen Saunthararajah; Giuseppina Nucifora
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy.

Authors:  T Pintado; M T Ferro; C San Román; M Mayayo; J G Laraña
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860

10.  Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.

Authors:  Katja Haas; Michael Kundi; Wolfgang R Sperr; Harald Esterbauer; Wolf-Dieter Ludwig; Richard Ratei; Elisabeth Koller; Helga Gruener; Cristina Sauerland; Christa Fonatsch; Peter Valent; Rotraud Wieser
Journal:  Genes Chromosomes Cancer       Date:  2008-04       Impact factor: 5.006
View more
  15 in total

1.  The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Authors:  Nina Fenouille; Christopher F Bassil; Issam Ben-Sahra; Lina Benajiba; Gabriela Alexe; Azucena Ramos; Yana Pikman; Amy S Conway; Michael R Burgess; Qing Li; Frédéric Luciano; Patrick Auberger; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Yi Zhang; Archibald S Perkins; Kevin Shannon; Michael T Hemann; Alexandre Puissant; Kimberly Stegmaier
Journal:  Nat Med       Date:  2017-02-13       Impact factor: 53.440

2.  The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Susumu Goyama; Yasuhiko Kamikubo; Souichi Adachi
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

3.  Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.

Authors:  Kazuhiro Maki; Fusako Sugita; Yuka Nakamura; Ko Sasaki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

4.  Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.

Authors:  Ryutaro Kotaki; Hiroshi Higuchi; Daisuke Ogiya; Yasuhiro Katahira; Natsumi Kurosaki; Naoko Yukihira; Jun Ogata; Haruna Yamamoto; Syakira Mohamad Alba; Azran Azhim; Tatsuo Kitajima; Shigeaki Inoue; Kazuhiro Morishita; Koh Ono; Ryo Koyama-Nasu; Ai Kotani
Journal:  Int J Hematol       Date:  2017-08-22       Impact factor: 2.490

5.  PRDM paralogs antagonistically balance Wnt/β-catenin activity during craniofacial chondrocyte differentiation.

Authors:  Lomeli C Shull; Ezra S Lencer; Hyun Min Kim; Susumu Goyama; Mineo Kurokawa; James C Costello; Kenneth Jones; Kristin B Artinger
Journal:  Development       Date:  2022-02-24       Impact factor: 6.868

6.  Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors:  Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

7.  Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Authors:  A Queisser; S Hagedorn; H Wang; T Schaefer; M Konantz; S Alavi; M Deng; W Vogel; A von Mässenhausen; G Kristiansen; S Duensing; J Kirfel; C Lengerke; S Perner
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

8.  Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.

Authors:  A Sayadi; J Jeyakani; S H Seet; C-L Wei; G Bourque; F A Bard; N A Jenkins; N G Copeland; E A Bard-Chapeau
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

9.  The conserved and divergent roles of Prdm3 and Prdm16 in zebrafish and mouse craniofacial development.

Authors:  Lomeli Carpio Shull; Rwik Sen; Johannes Menzel; Susumu Goyama; Mineo Kurokawa; Kristin Bruk Artinger
Journal:  Dev Biol       Date:  2020-02-08       Impact factor: 3.582

10.  The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.

Authors:  Norio Yamakawa; Kazuko Kaneda; Yusuke Saito; Emi Ichihara; Kazuhiro Morishita
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.